
Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer
ByA. William Blackstock, Jr, MD,Susan A. Melin, MD,Jerome M. Butler, MD,Suzanne Patton, MD,Benjamin Pineau, MD,David Albertson, MD,Russell Howerton, MD,Edward Levine, MD
Published: | Updated:
Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.
